|
Immupharma PLC on Monday announced the filing of a ‘groundbreaking’ new patent application for its lead asset P140, the world’s first immunormalizer. In response, shares in the specialist drug discovery and development company more than doubled to 4.76 pence each in London for a market value of £19.8 million. London-based Immupharma said the patent application, which provides the potential for 20 years of commercial exclusivity, discloses a novel diagnostic test and precision treatment approach, identifying a subpopulation of patients with type M immune disorder that are P140 super-responders. This approach can be used to treat up to 50 autoimmune diseases, representing a major step forward in precision medicine. The new diagnostic test is expected to shorten the time to diagnosis, improve patient selection for clinical trials, and enable smaller, faster, and more successful trials, significantly increasing the probability of regulatory approval. P140 is an immunormalizer and works by restoring immune homeostasis, the finely regulated balance of the immune system. Autoimmune diseases are characterised by an imbalance in the immune system. In type M patients, treatment with P140 directly normalises this imbalance, leading to a stable and healthy immune response. Immupharma said autoimmune diseases affect more than 400 million people worldwide, with a therapeutic market valued at over $100 billion annually. Current treatments remain ‘limited and often unsafe,’ the firm said, highlighting an unmet medical need. Chief Executive Tim McCarthy said the discovery of a new mechanism of action and identification of type M greatly expands the scope of P140 across a wide range of autoimmune diseases and the filing of a patent application ‘significantly enhances’ the business case due to the potential for long-term increased revenues. ‘This combination makes P140 a unique and extremely valuable asset, particularly with the potential for 20 years of commercial exclusivity, and will add enormous traction to our current discussions with potential global partners of P140,’ he added. Reflecting the ‘significance’ of the announcement, Immupharma has promoted Sebastien Goudreau to chief scientific officer and Laura Mauran-Ambrosino to head of research and development. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
